COVID-19 vaccine latest updates: Astrazeneca’s manufacturing ‘error’ raises concerns on vaccine efficacy, Covaxin to begin phase III trials in Gujarat
- Astrazeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine.
- Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, will begin its phase III trials at the Sola civil hospital in Ahmedabad, Gujarat.
- Pfizer begins process to register its COVID-19 vaccine in Brazil.
Here’s a look at COVID-19 vaccine updates from around the world —
Astrazeneca admits manufacturing ‘error’ in vaccine
AstraZeneca and Oxford University have acknowledged a manufacturing error that is raising questions about preliminary results of their experimental COVID-19 vaccine.
AdvertisementA statement describing the error on November 25 comes days after the company and the university described the shots as "highly effective" and made no mention of why some study participants didn't receive as much vaccine in the first of two shots as expected.
The group of volunteers that got a lower dose seemed to be much better protected than the volunteers who got two full doses. Astrazeneca said that in the low-dose group, the vaccine appeared to be 90%effective. Whereas the group that got two full doses, the vaccine appeared to be 62% effective. The drugmakers said that combined, the vaccine appeared to be 70% effective.
Covaxin reaches Gujarat for phase III trials
Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, will begin its phase III trials at the Sola civil hospital in Ahmedabad, Gujarat. The hospital has received 500 doses of the vaccine candidate for the trial, Gujarat deputy CM Nitin Patel said.
The vaccine will be tested on healthy and elderly volunteers and health workers. They will receive two doses of the potential vaccine per month during this trial. Covaxin is being developed by the Hyderabad-based firm in collaboration with the Indian Council of Medical Research (ICMR).
Pfizer begins process to register its COVID-19 vaccine in Brazil
Pfizer has started the process to register its COVID-19 vaccine in Brazil. It has submitted the results of its tests to the country’s health regulators. "This is an important step so that the vaccine can be available in Brazil," Pfizer said in a statement.
AdvertisementPfizer’s COVID-19 vaccine candidate is being developed in collaboration with the German pharmaceutical BioNTech.
Sinopharm applies for license to bring its vaccine to the market for public use
Sinopharm’s subsidiary, China National Biotec Group, has applied to the country’s health regulators to bring its COVID-19 vaccine candidate to the market for public use, according to reports. The application may include data from the company’s phase III trials conducted in the Middle East and South America. However, the company has not made the results of the vaccine's efficacy public yet.
Advertisement(with inputs from agencies)
SEE ALSO: US stocks dip from record levels on disappointing economic data and soaring COVID-19 cases
Diego Maradona, one of the greatest stars in soccer history, has died at the age of 60
- Andhra ASHA worker's death following Covid jab triggers protest
- Downloadable e-version of voter identity card to be launched on January 25
- Covid-19 test mandatory for guests attending Varun Dhawan's wedding
- First confirmed case of COVID-19 in pet reported in South Korea
- All iPhone 13 models to come with sensor-shift camera stabilisation, says report